Dean discusses the role of BTK inhibitors in the management of CLL and the importance of molecular profiling for treatment rechallenge decisions.
Asad Dean, MD
Advertisement
Asad Dean, MD, is a physician at Texas Oncology and an assistant professor in the Division of Hematology/Oncology at UT Southwestern Medical Center.
Articles by Asad Dean, MD
Asad Dean, MD, discusses the role of pirtobrutinib in second-line CLL.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
4
Dr Le on Choosing Between Zongertinib and Sevabertinib in HER2 TKD–Mutant NSCLC
5